Today: 6 November 2025
Subscribe
Browse Tag

pharmaceutical industry

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus (~$0.63–$0.64) reuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecasts (~$16.5B) stocktwits.com reuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates. Encouraged by the quarter’s results,
4 November 2025
 ·  ·  ·  ·  · 
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the news gurufocus.com. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97 marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past year marketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this
21 October 2025
 ·  ·  ·  · 
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range. The catalyst was clear: on Sept. 30 Trump’s administration announced the Pfizer pricing deal, and PFE instantly rallied. Shares jumped about 6–7% on
19 October 2025
 ·  ·  ·  ·  ·  · 
ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday (Oct 17) alone, finishing at $6.45 marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcements nasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours
18 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Go toTop